Levemir is the brand name for insulin detemir, a long-acting basal insulin analog that Novo Nordisk sold in the United States from 2005 until its full withdrawal in 2024. Novo Nordisk notified the FDA on November 8, 2023, that it would stop manufacturing Levemir, citing global manufacturing constraints and declining formulary coverage as insurers steered patients toward newer basal insulins. The FlexPen device faced supply disruption starting in mid-January 2024 and was formally discontinued on April 1, 2024. Levemir vials remained available through pharmacies until December 31, 2024, when Novo Nordisk stopped shipping them entirely. As of 2026, no US pharmacy, wholesaler, or hospital can order new Levemir stock; any bill or pharmacy record showing a current Levemir fill is either an old prescription being reprocessed or a billing error.
Novo Nordisk sent patients a direct letter naming several replacement options, though most of those options reduce to two molecules: insulin glargine (Lantus, Basaglar, Semglee, Rezvoglar) and insulin degludec (Tresiba). Tresiba is the company's own recommended switch and, unlike Levemir, is not approved for twice-daily dosing, so patients who took Levemir twice a day need a dosing conversation with their prescriber before switching. Tresiba's 2026 list price runs $339 for a 10 mL vial up to $610 for a five-pack of FlexTouch pens, several times higher than Levemir's final discounted price of $108 to $162. Patients moving off Levemir should also review the insulin cost guide and the Lantus cost guide for a side-by-side look at glargine pricing and biosimilar options like Semglee.
Federal drug-pricing policy did not cause Levemir's disappearance and offers no path back. Levemir was never selected for Medicare price negotiation under the Inflation Reduction Act of 2022, in either the 10 Round-1 drugs effective January 1, 2026, or the semaglutide-focused Round 2 drugs effective 2027, so there is no Maximum Fair Price to look up. What does still apply is the IRA's separate insulin provision: the $35-per-month Medicare Part D cap on insulin out-of-pocket costs, effective since January 1, 2023. That cap now protects whatever basal insulin you switched to, and the 2026 annual Part D out-of-pocket cap of $2,100 across all covered drugs applies on top of it. Medicaid, which covers basal insulin in all 50 states, is unaffected by the Levemir discontinuation beyond requiring a formulary update to the replacement product.
What Levemir Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same levemir can cost many times more at a hospital than at your local pharmacy:
2026 Levemir Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (Levemir stock) | Not available in 2026 | Novo Nordisk stopped manufacturing Levemir; FlexPens ended April 1, 2024, and vials ended December 31, 2024. No US pharmacy can fill a new Levemir prescription. |
| Pharmacy counter (Tresiba replacement, cash) | $339 - $610/month | Retail cash price for Tresiba (insulin degludec), Novo Nordisk's recommended Levemir replacement, per vial or 5-pack FlexTouch box, 2026 list price. |
| Medicare Part D (2026) | $35/month maximum (IRA insulin cap) | Applies to whichever covered basal insulin replaces Levemir. No deductible phase for insulin under the Inflation Reduction Act. |
| Commercial insurance | $0 - $75/month copay | Formulary tier and prior authorization vary by plan for Tresiba or a glargine alternative; step therapy toward a biosimilar is common. |
| Medicaid | $1 - $4/prescription | Covered in all 50 states for the replacement basal insulin; copay and formulary specifics vary by state Medicaid agency. |
Levemir prices reflect the final 2024 list price before discontinuation. Tresiba and coverage figures reflect 2026 GoodRx and NovoCare pricing data.
Source: CMS Part D 2026 benefit design, NovoCare pricing pages, GoodRx
Why Hospitals Charge So Much
Hospitals cannot bill for Levemir on a 2026 admission because no hospital pharmacy can obtain it; distributors stopped shipping the drug after December 31, 2024. Patients admitted for any reason who previously used Levemir at home are now switched to whatever basal insulin the hospital formulary carries, typically Lantus, a glargine biosimilar, or Tresiba, administered under the same Diagnosis-Related Group (DRG) bundled payment that covered Levemir before. Under Medicare's DRG system, the insulin cost is folded into the flat per-admission payment, so most Medicare and commercially insured inpatients should not see a separate line-item charge for basal insulin at all.
Billing systems that have not been updated can still generate a Levemir line item from an old chargemaster entry even when the patient actually received a substitute like Tresiba or Lantus. If your itemized bill lists Levemir at $400 to $1,200 or more for an admission, ask the billing department for the National Drug Code (NDC) on that line. A Levemir NDC on a 2026 bill is a data-entry error, since the product cannot have been physically dispensed. Request a corrected bill reflecting the insulin you actually received, and use the medical bill analyzer to flag the discrepancy if the hospital does not correct it promptly.
Patient Assistance Programs
Novo Nordisk still runs two assistance programs that apply to Levemir's replacement products (Tresiba, NovoLog, and others in the Novo Nordisk portfolio), even though Levemir itself is no longer manufactured. Which program fits your situation depends on your insurance status and income.
Patient assistance programs for Levemir| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Novo Nordisk Patient Assistance Program (NovoCare PAP) | Free Tresiba or another qualifying Novo Nordisk insulin for Medicare beneficiaries or uninsured patients with household income at or below 400% FPL | novocare.com/pap |
| Novo Nordisk MyInsulinRx Savings Program | $35 for up to a 90-day supply (3 vials or 2 pen packs) of covered Novo Nordisk insulins, including Tresiba, via a manufacturer coupon for commercially insured or cash-paying patients | novocare.com/myinsulinrx |
| NeedyMeds Drug Discount Card | Variable discount on basal insulin accepted at most US pharmacies; free to obtain | needymeds.org |
Federal anti-kickback statute (42 U.S.C. § 1320a-7b) bars Medicare, Medicaid, TRICARE, and VA beneficiaries from using manufacturer copay savings cards like MyInsulinRx. That statute does not block the income-based NovoCare Patient Assistance Program, which remains open to Medicare beneficiaries and the uninsured who meet the 400% FPL income threshold. If you have commercial insurance, use MyInsulinRx instead of the PAP.
Source: NovoCare patient assistance and savings program pages, NeedyMeds.org
Medicare Part D Coverage for Levemir
Medicare Part D capped insulin out-of-pocket costs at $35 per month for every covered insulin product starting January 1, 2023, under the Inflation Reduction Act of 2022. That cap applied to Levemir while it was still sold and now applies automatically to whichever covered basal insulin your plan substitutes, whether that is Tresiba, Lantus, or a glargine biosimilar. The $35 cap holds across every benefit phase, meaning you never pay a deductible-phase price for insulin, and it applies independently of the broader 2026 Part D annual out-of-pocket cap of $2,100 across all your covered drugs.
Part D plans updated their formularies to remove Levemir after Novo Nordisk's discontinuation notice, so if your 2026 plan documents still list Levemir, that listing is outdated. Your plan should have automatically transitioned you to a covered alternative, but some plans require a new prior authorization for Tresiba or a step-therapy trial of a lower-cost glargine biosimilar first. If your prescriber believes you need Tresiba specifically because of your prior twice-daily Levemir regimen, ask them to document that clinical history in the prior authorization request.
Levemir was never included in any round of Medicare drug price negotiation under the Inflation Reduction Act. CMS's Round 1 negotiated prices, effective January 1, 2026, cover 10 different drugs (including Fiasp and NovoLog, two other Novo Nordisk insulins), and Round 2 focuses on semaglutide products effective 2027. Insulin detemir was excluded from consideration entirely once Novo Nordisk announced discontinuation, since a negotiated Maximum Fair Price only applies to drugs still on the market.
Common Levemir Billing Errors
If you received a 2026 bill or Explanation of Benefits referencing Levemir, check for these issues before paying:
- Levemir NDC billed on a 2026 claim: this product cannot have been dispensed since supply ended December 31, 2024. Ask for a corrected claim showing the actual insulin dispensed.
- Deductible-phase copay charged for the replacement insulin: under the IRA, insulin has no Part D deductible phase. A deductible-phase charge for Tresiba or any covered basal insulin is a billing error.
- Prior authorization denial citing Levemir specifically rather than the replacement product: some plan systems have not fully updated formulary logic; ask the plan to re-run the review against the current formulary.
- MyInsulinRx savings card not applied at the pharmacy counter for Tresiba despite active enrollment: ask the pharmacist to rerun the claim using the program's BIN/PCN number.
- Inpatient basal insulin billed separately from the DRG rate: most hospital insulin charges should be bundled into the flat DRG payment for Medicare and commercial insurance.
Frequently Asked Questions
Is Levemir still available in 2026?
No. Novo Nordisk fully discontinued Levemir (insulin detemir) in the United States. The FlexPen was discontinued April 1, 2024, and vials stopped shipping after December 31, 2024, due to manufacturing constraints and shrinking insurance formulary coverage. No US pharmacy, wholesaler, or hospital can obtain new Levemir stock in 2026. Patients who used Levemir have switched to Tresiba, Lantus, or a glargine biosimilar under their prescriber's guidance.
Is there a generic or biosimilar for Levemir?
No. Insulin detemir has never had an approved generic or biosimilar, and none is in development, because Levemir was withdrawn for commercial reasons in 2024 rather than patent expiration. Patients need a replacement basal insulin: Tresiba (insulin degludec) has no biosimilar either, while insulin glargine products (Lantus, Basaglar, Semglee, Rezvoglar) do have FDA-approved biosimilars available at lower cost.
How do I apply for the Novo Nordisk patient assistance program now that Levemir is gone?
Call 1-866-310-7549 or visit novocare.com to request the Patient Assistance Program application for Tresiba or another qualifying Novo Nordisk insulin. You will need proof of household income, proof of Medicare enrollment or no prescription drug insurance, a signed prescription, and proof of US residency. Both you and your prescriber must sign the form. Processing takes 7 to 14 business days, and household income must be at or below 400 percent of the Federal Poverty Level.
Can I use the Tresiba MyInsulinRx savings card with Medicare?
No. Federal anti-kickback law bars Medicare, Medicaid, TRICARE, and VA beneficiaries from using manufacturer copay savings cards like MyInsulinRx. Medicare beneficiaries instead pay the statutory $35-per-month insulin cap through their Part D plan. If that amount is still unaffordable, apply for the income-based NovoCare Patient Assistance Program, which remains open to Medicare enrollees.
What if my insurance denies coverage for Tresiba or another Levemir replacement?
Request a written denial notice, then file a formal appeal within 60 days. Ask your prescriber to request a peer-to-peer clinical review documenting your prior Levemir regimen and why the replacement is medically necessary. If your plan requires step therapy toward a glargine biosimilar first, your prescriber can file a step-therapy override. If the internal appeal fails, escalate to an external review through your state Department of Insurance.
Does the IRA negotiated Medicare price apply to Levemir?
No. Levemir was never selected for Medicare price negotiation under the Inflation Reduction Act, in either the 10 Round-1 drugs effective January 1, 2026, or the Round 2 semaglutide drugs effective 2027. It was excluded once Novo Nordisk announced discontinuation. Levemir did benefit from the IRA's separate $35-per-month insulin cap while it was sold, and that cap now applies to your replacement basal insulin instead.
What does Levemir cost without insurance at the pharmacy counter in 2026?
Levemir cannot be purchased in 2026 at any price; it was fully discontinued by December 31, 2024. Its final US list price was $108 per 10 mL vial and $162 per 5-pack FlexPen box. Patients now needing a long-acting basal insulin should compare Tresiba, which retails for $339 to $610 per month, against lower-cost glargine biosimilars like Semglee, available for a fraction of that price with a GoodRx coupon.
Do I qualify for the NovoCare patient assistance program for Tresiba?
You qualify if you have Medicare or no prescription drug insurance, your household income is at or below 400 percent of the Federal Poverty Level, and you are not eligible for or enrolled in Medicaid or VA benefits. For 2026, the income limit is $63,840 for a household of one, $132,000 for a household of four, and $222,880 for a household of eight. Patients with commercial insurance use the MyInsulinRx savings card instead.
